Efficacy and Safety Study of Lurbinectedin and Dostarlimab in Cancer Patients: Protocol VHIO21001 - LiDer

NCT06385548 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped IMP owner decision

Conditions

Endometrial Cancer

Interventions

DRUG: Lurbinectedin
DRUG: Dostarlimab

Sponsor

Vall d'Hebron Institute of Oncology